Actively Recruiting
Study Comparing KPD Consolidation Therapy After Stem Cell Transplant Versus No Consolidation in Adults With Newly Diagnosed Multiple Myeloma Eligible for Transplant
Led by Peking University People's Hospital · Updated on 2025-03-17
202
Participants Needed
3
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
The trial investigates newly diagnosed multiple myeloma MM patients who are eligible for transplantation. It aims to compare the effects of post-transplant consolidation therapy using the KPD regimen carfilzomib, pomalidomide, and dexamethasone against no consolidation, followed by maintenance therapy. The goal is to understand differences in minimal residual disease MRD negativity rates and overall treatment outcomes in these patients. Participants are randomly assigned to receive either two cycles of KPD consolidation therapy after autologous stem cell transplantation ASCT followed by maintenance treatment or direct maintenance therapy without consolidation. This approach helps clarify whether adding consolidation therapy after transplant improves treatment success compared to maintenance alone. Throughout the study, patients undergo assessments to measure MRD negativity and overall response rates at 36 months. Additional evaluations include progression-free survival and overall survival. Participants are monitored regularly for treatment effects, safety, and adherence to study procedures, with the total duration extending to at least 36 months after maintenance therapy begins.
CONDITIONS
Brief Title
KPD Consolidation After ASCT in NDMM Patients
Research Team
X
Xuelin Dou, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here